Almirall, S.A. (ALMRY) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day and thank you for standing by. Welcome to the Admiral Full Year 2025 Earnings Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1 1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1 1 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Pablo Dibason, Head of Investor Relations. Please go ahead. Thank you very much, Sandra, and good morning, everyone. Thank you for joining us for today's quarterly earnings update and review of Almirals' full-year financial results of 2025. As always, we are sharing the slides we are using today in the investor section of our website at almiral.com. Please move to slide number two. Let me remind you that the information presented in this call contains forward-looking statements which involve known and unknown risk, uncertainties, and other factors that may cause actual results to materially differ from what we are sharing today. Please move to slide number three. Presenting today, Carlos Gallardo, Chairman and Chief Executive Officer, John Garay, Chief Financial Officer, and Carl Sigabar, Chief Specific Officer. Carlos will start with the guidance and business highlights of 2025, followed by an update specifically on biologics and the key growth drivers of our medical dermatology portfolio. Carl will provide you with an update on the pipeline and R&D programs. John will then walk through the financials before Carlos concludes the presentation, and we open for questions. I will hand over to Carlos Gallard...